.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Novartis
Deloitte
Farmers Insurance
Covington
McKinsey
US Army
Healthtrust
McKesson
QuintilesIMS

Generated: September 21, 2017

DrugPatentWatch Database Preview

PERTOFRANE Drug Profile

« Back to Dashboard

Which patents cover Pertofrane, and what generic Pertofrane alternatives are available?

Pertofrane is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in PERTOFRANE is desipramine hydrochloride. There are nine drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the desipramine hydrochloride profile page.

Summary for Tradename: PERTOFRANE

Patents:0
Applicants:1
NDAs:1
Bulk Api Vendors: see list29
Clinical Trials: see list1
Patent Applications: see list1,019
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:PERTOFRANE at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us
PERTOFRANE
desipramine hydrochloride
CAPSULE;ORAL013621-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Sanofi Aventis Us
PERTOFRANE
desipramine hydrochloride
CAPSULE;ORAL013621-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: PERTOFRANE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us
PERTOFRANE
desipramine hydrochloride
CAPSULE;ORAL013621-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Sanofi Aventis Us
PERTOFRANE
desipramine hydrochloride
CAPSULE;ORAL013621-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Sanofi Aventis Us
PERTOFRANE
desipramine hydrochloride
CAPSULE;ORAL013621-002Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Sanofi Aventis Us
PERTOFRANE
desipramine hydrochloride
CAPSULE;ORAL013621-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
Teva
Cipla
Federal Trade Commission
Novartis
Cantor Fitzgerald
US Army
AstraZeneca
Fish and Richardson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot